sorafenib has been researched along with 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol) | Trials (3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol) | Recent Studies (post-2010) (3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 12 | 0 | 12 |
| Protein | Taxonomy | sorafenib (IC50) | 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol (IC50) |
|---|---|---|---|
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | 0.0343 | |
| TGF-beta receptor type-1 | Homo sapiens (human) | 1.84 | |
| Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | 0.0018 | |
| Activin receptor type-1 | Homo sapiens (human) | 0.0181 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
1 other study(ies) available for sorafenib and 3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
| Article | Year |
|---|---|
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |